
18F-FDG PET/CT detects approximately 73% of tumor lesions, while 68Ga-FAPI finds approximately 94%.
Ashley Gallagher is an editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
18F-FDG PET/CT detects approximately 73% of tumor lesions, while 68Ga-FAPI finds approximately 94%.
Analysis indicates 4 peptides had significant or nearly significant seropositivity, all of which were associated with membrane and spike proteins of SARS-COVID-2.
Study results shows that the use of a point-of-care tool and timely after care were essential to lowering the risk of hospitalization from cardiovascular disease within 30 days after acute HF.
Analysis focuses on why some individuals with a genetic predisposition develop AMD, while others are spared.
Study is the first to examine calciferol in brain tissue, which may help investigators understand dementia and its causes.
Analysis focuses on causal effects while accounting for other environmental and genetic factors, such as a family history and socioeconomic disadvantages.
Analysis indicates that for individuals older than aged 40 years, the risk is cumulative and greatest 1 to 2 years after use.
Risk is highest for those who are obese or who have diabetes, investigator from Keck Medicine and the University of Southern California indicate.
Analysis demonstrates that the tablets can significantly reduce the animals’ blood glucose levels for more than 5 hours.
Analysis shows 4-week daily dietary supplementation with the nuts increases the level of beneficial 12,13-DiHOME after physical activity.
Data are based on tests using low-cost, simple blood tests for helping decide which individuals with the disease need treatment.
Analysis indicates that Acadia Pharmaceuticals Inc’s pimavanserin is the only FDA-approved medication for the treatment of delusions and hallucinations associated with PDP.
Study meets primary and key secondary endpoints, showing clinically meaningful and statistically significant improvements.
The biopsy test is the first companion diagnostic approved for entrectinib for individuals who do not have an available tissue sample.
Mothers, in particular, benefit when they are given longer leaves and policies that offer incentives or wage replacement, analysis indicates.
Results show an association between linoleic acid, found in nuts, seeds, and vegetable oils, and increased hypersensitivity in psoriatic lesions.
Ublituximab-xiiy from TG Therapeutics Inc is the first anti-CD20 monoclonal antibody approved for individuals with RMS that is administered as a 1-hour infusion after the starting dose.
The findings show promising clinical activity and a favorable tolerability profile in the treatment of KRASG12C-mutated advanced colorectal cancer.
MenABCWY combines components of 2 vaccines, which help protect against serogroups that cause most cases of the invasive disease.
First direct evidence of diminished 5-HT release proves hypothesis, according to a new analysis published in Biological Psychiatry.
Without company or insurance contracts, controlled medication prices reduce burden on patients.
The National Institute of Health’s grant funds a phase 2 clinical trial of doxycycline in a large group of individuals with the 2 conditions who are smokers or used to smoke.
Results show possible impact of using Janssen Pharmaceuticals’ ibrutinib in the front-line setting, providing additional data on chronic lymphocytic leukemia therapies.
From newsworthy moments to groundbreaking research, these are the most popular articles in the zoster space, published on Pharmacy Times® during 2022.
Intravenous tocilizumab (Actemra; Genentech) has been approved for the treatment of COVID-19 in individuals who are hospitalized and receiving systemic corticosteroids and supplemental oxygen.
Calcitriol may offer protection from the harmful effects of the chemical in drinking water, analysis shows.
The protein is vitally important and could be a prognostic indicator and potential therapeutic target.
TD2 remission is defined as a hemoglobin A1C level of less than 6.5% at least 1 year after stopping medication, investigators say.
From newsworthy moments to groundbreaking research, these are the most popular articles in the cholangiocarcinoma space, published on Pharmacy Times® during 2022.
Recommendations for the management of bile duct cancer benefit authorities, patients, and physicians, but investigators say more research is needed.